ITERUM THERAPEUTICS PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.67 USD | +6.37% |
|
+16.78% | -15.23% |
Presentation Operator MessageOperator (Operator)Hello, everyone, and welcome to the Iterum The...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Iterum Therapeutics plc is a clinical-stage pharmaceutical company. The Company develops differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. It is advancing its first compound, sulopenem, a novel penem anti-infective compound, in Phase 3 clinical development with an oral formulation. Sulopenem is a potent, thiopenem antibiotic delivered intravenously, which is active against bacteria that belong to the group of organisms known as gram-negatives and causes urinary tract and intra-abdominal infections. It has also developed sulopenem in an oral tablet formulation, sulopenem etzadroxil-probenecid. Sulopenem also has an IV formulation. Sulopenem has demonstrated potent in vitro activity against a variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics.
Calendar
2024-05-09
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
1.67
USD
Average target price
6.5
USD
Spread / Average Target
+289.22%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -15.23% | 27.65M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- ITRM Stock
- News Iterum Therapeutics plc
- Transcript : Iterum Therapeutics plc, Q4 2023 Earnings Call, Mar 28, 2024
